Somatostatin analog: Effects on hypergastrinemia and hypercalcitoninemia

G. W. Geelhoed, Barbara L. Bass, S. L. Mertz, K. L. Becker

Research output: Contribution to journalArticlepeer-review

12 Scopus citations


A somatostatin analog (SMS 201-995) was used to treat symptomatic patients with a residual tumor burden of gastrinoma or medullary thyroid carcinoma and pathologic elevations of circulating marker peptides associated with these neuroendocrine tumors. Possible inhibitory effects of the analog on marker peptides, patients' symptoms, or tumor progression were studied in a dose-response protocol and during several months of self-injection of SMS 201-995. Both patients reported remarkable relief of secretory diarrhea and other symptoms, and serum gastrin was successfully suppressed by increasing doses of the analog. However, no effect was seen in reduction of hypercalcitoninemia. Morphologic imaging of residual tumor showed no progression of medullary thyroid carcinoma during treatment and, in the case of hepatic gastronoma metastases, remarkable tumor regression was confirmed. No toxicity or glucose intolerance was experienced. Somatostatin analog shows promise for palliative management of endocrinologic symptoms due to neuroendocrine tumors, and an inhibitory effect can be measured in some but not all peptide markers. Further evidence of its negative trophic effect on tumor blood flow may suggest an antineoplastic potential, as well as palliative use of this new treatment.

Original languageEnglish (US)
Pages (from-to)962-970
Number of pages9
Issue number6
StatePublished - Dec 1 1986

ASJC Scopus subject areas

  • Surgery


Dive into the research topics of 'Somatostatin analog: Effects on hypergastrinemia and hypercalcitoninemia'. Together they form a unique fingerprint.

Cite this